价格

Tillotts Pharma Ag

ACTIVE

Utländsk Adr - Foreign Addr, 瑞典www.tillotts.comSubsidiary501–1,000 名员工成立于: 1986-01-01

别名:

tillotts services

tillotts pharma gmbh

隶属于 ZERIA PHARMACEUTICAL CO., LTD.

概览

试验阶段分布

阶段

试验数

占比

1 期

64.3%

3 期

28.6%

试验状态分布

进行中（未招募）

53.6%

已完成

46.4%

相关临床试验

该机构主办的试验（28）

Real-World-Data describing the escalation and deescalation of the dosage of 1600 mg mezalazine tablets in the therapy of an acute flare in ulcerative colitis

已完成

observational

May 202186 名受试者

Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules

Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.

1 期

进行中（未招募）

Mar 2015817 名受试者

Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.

1 期

进行中（未招募）

May 2014800 名受试者

Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.

1 期

进行中（未招募）

Mar 2014800 名受试者

Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.

1 期

进行中（未招募）

Feb 2014800 名受试者

Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.

1 期

进行中（未招募）

Jan 2014800 名受试者

Study to test whether TP05 at a dose of 3.2 g/day is safe, well-tolerated and works as a treatment for active Ulcerative Colitis. Treatment will be assigned by chance and patients and investigators will not know whether the patients are receiving TP05 or the standard therapy. This blinded period will be followed by a period where all patients receive TP05.

1 期

进行中（未招募）

Nov 2013800 名受试者

第 1 页，共 4 页

药物批准

按机构分类的批准

NMPA

National Medical Products Administration

药物批准

EMA

European Medicines Agency

药物批准

CANADA

Health Canada

药物批准

SFDA

Saudi Food and Drug Authority

药物批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

药物批准

近期批准

ASACOL

SFDA

2025-07-18

DIFICLIR 200 mg Film Coated Tablet

SFDA

2025-07-18

Mesalazine Enteric-coated Tablets

NMPA

2025-04-15

Mesalazine Enteric-coated Tablets

DIFICLIR 40 MG/ML GRANULADO PARA SUSPENSION ORAL

CIMA_AEMPS

2020-05-13

Mesalazine Enteric-coated Tablets

NMPA

2020-04-23

Mesalazine Enteric-coated Tablets

NMPA

2020-04-23

资讯

暂无资讯文章

返回机构列表